M. Henry
Role not yet determined Is this you? Add your title
Also affiliated: Argonne National Laboratory (2024); Michael E. DeBakey VA Medical Center (2014); DuPont (United States) (1989–1990); Plant & Food Research (2005); UF Health Shands Hospital (2023); Baylor College of Medicine (2014); University of Ibadan (2018); Medical College of Wisconsin (2023); University of Michigan (2015); North Shore University Hospital (1972); Health Protection Scotland (2006–2007); Nassau University Medical Center (1972); North Shore Hospital (1972); Cork University Hospital (1998); University of Florida (2022–2023); St Francis’ Hospital (2019); St. Francis Hospital (2019–2025); Experimental Station (1990); Cook Research (United States) (2002); Elanco (United States) (1992); St Francis Chronic Hospital (2019); Dow Chemical (United States) (2002); Hôpital Raymond-Poincaré (2007); St. Luke's Hospital (2014); Hôpital Jeanne d'Arc (1972–1978); St. Francis Referral Hospital (2019); Naggalama Hospital (2019); Marymount University (1973); The University of Texas Medical Branch at Galveston (1967); University of Maryland, College Park (1979–1990); University of Otago (2005); Florida College (2022–2023)
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
M. Henry's research has explored diverse scientific areas, as evidenced by publications spanning plant pathology, medical interventions, and cellular biology. Early work includes investigations into the causal role of *Xylella fastidiosa* in oleander leaf scorch disease and the transport of sugars in wheat powdery mildew. More recent publications address the endovascular repair of the ascending aorta and the attenuation of apoptosis in Chinese hamster ovary cells for biopharmaceutical production. Henry also has a publication examining the association between depression symptoms and opioid use in chronic pain patients. With an h-index of 17, 90 total publications, and over 1,000 citations, Henry has collaborated with researchers at the University of Arkansas for Medical Sciences, including Milan Bimali, Songthip Ounpraseuth, Jaime Baldner, and Kristin Gaffney.
Metrics
- h-index: 17
- Publications: 90
- Citations: 1,067
Selected Publications
-
Study protocol for a pilot study for Remote ADHD Monitoring Program (RAMP) for children in rural areas (2025)
-
The protocol for a pilot feasibility trial of Improving Neurodevelopmental ouTcomes After prenatal Cannabinoid in uTero exposure (INTACT) study for a multi-center trial (2025)
-
Real-world comparative outcomes of EGFR-TKIs for first-line treatment of EGFR+ metastatic non–small-cell lung cancer (2025)
-
Real-World Comparative Outcomes of Egfr-Tkis for First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer (2024)
-
Characterization of the Immune Impact of Daratumumab By Mass Cytometry in Multiple Myeloma (2018)
-
Expression Signature of Myeloma Residual Cells Is Characterized By Genes Associated with Proliferation, Epigenetic Modification, and Stem Cell Maintenance (2018)
Federal Grants 1
Epigenetic Regulation of Differentially Expressed Genes in Cutaneous T Cell Lymphoma
Collaboration Network
Top Collaborators
- Expression Signature of Myeloma Residual Cells Is Characterized By Genes Associated with Proliferation, Epigenetic Modification, and Stem Cell Maintenance
- Characterization of the Immune Impact of Daratumumab By Mass Cytometry in Multiple Myeloma
- Expression Signature of Myeloma Residual Cells Is Characterized By Genes Associated with Proliferation, Epigenetic Modification, and Stem Cell Maintenance
- Characterization of the Immune Impact of Daratumumab By Mass Cytometry in Multiple Myeloma
- Expression Signature of Myeloma Residual Cells Is Characterized By Genes Associated with Proliferation, Epigenetic Modification, and Stem Cell Maintenance
- Characterization of the Immune Impact of Daratumumab By Mass Cytometry in Multiple Myeloma
- Expression Signature of Myeloma Residual Cells Is Characterized By Genes Associated with Proliferation, Epigenetic Modification, and Stem Cell Maintenance
- Characterization of the Immune Impact of Daratumumab By Mass Cytometry in Multiple Myeloma
- Real-World Comparative Outcomes of Egfr-Tkis for First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer
- Real-world comparative outcomes of EGFR-TKIs for first-line treatment of EGFR+ metastatic non–small-cell lung cancer
- Real-World Comparative Outcomes of Egfr-Tkis for First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer
- Real-world comparative outcomes of EGFR-TKIs for first-line treatment of EGFR+ metastatic non–small-cell lung cancer
- Real-World Comparative Outcomes of Egfr-Tkis for First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer
- Real-world comparative outcomes of EGFR-TKIs for first-line treatment of EGFR+ metastatic non–small-cell lung cancer
- Real-World Comparative Outcomes of Egfr-Tkis for First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer
- Real-world comparative outcomes of EGFR-TKIs for first-line treatment of EGFR+ metastatic non–small-cell lung cancer
- Real-World Comparative Outcomes of Egfr-Tkis for First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer
- Real-world comparative outcomes of EGFR-TKIs for first-line treatment of EGFR+ metastatic non–small-cell lung cancer
- Real-World Comparative Outcomes of Egfr-Tkis for First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer
- Real-world comparative outcomes of EGFR-TKIs for first-line treatment of EGFR+ metastatic non–small-cell lung cancer
- Real-World Comparative Outcomes of Egfr-Tkis for First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer
- Real-world comparative outcomes of EGFR-TKIs for first-line treatment of EGFR+ metastatic non–small-cell lung cancer
- Real-World Comparative Outcomes of Egfr-Tkis for First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer
- Real-world comparative outcomes of EGFR-TKIs for first-line treatment of EGFR+ metastatic non–small-cell lung cancer
- Real-World Comparative Outcomes of Egfr-Tkis for First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer
- Real-world comparative outcomes of EGFR-TKIs for first-line treatment of EGFR+ metastatic non–small-cell lung cancer
- Real-World Comparative Outcomes of Egfr-Tkis for First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer
- Real-world comparative outcomes of EGFR-TKIs for first-line treatment of EGFR+ metastatic non–small-cell lung cancer
- Real-World Comparative Outcomes of Egfr-Tkis for First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer
- Real-world comparative outcomes of EGFR-TKIs for first-line treatment of EGFR+ metastatic non–small-cell lung cancer
Similar Researchers
Based on overlapping research topics